Defective anchoring of JNK1 in the cytoplasm by MKK7 in Jurkat cells is associated with resistance to Fas-mediated apoptosis

Jing Wang*, Ruirong Tang*, Ming Lv*, Qingyang Wang, Xueying Zhang, Yuanyuan Guo, Hong Chang, Chunxia Qiao, He Xiao, Xinying Li, Yan Li, Beifen Shen, and Jiyan Zhang
Department of Molecular Immunology, Institute of Basic Medical Sciences, Beijing 100850, China

ABSTRACT The c-Jun N-terminal protein kinase (JNK) plays a context-dependent role in tumorigenesis. Stress-induced redistribution of JNK from the cytoplasm to the nucleus has been demonstrated as essential for stress-induced cell death. However, accumulation of basal JNK activity in the nucleus has frequently been seen in tumor cells. Our previous report revealed aberrant nuclear entry of JNK protein in Jurkat human leukemic T-cells even without JNK hyperactivation. Because inhibition of JNK activity, especially JNK1 activity, in Jurkat cells results in augmented Fas-mediated apoptosis, it is possible that aberrant subcellular localization of JNK, especially the JNK1 isoform, contributes to the resistance to Fas-mediated apoptosis. Here we report that MKK7 works as a cytoplasmic anchoring protein for JNK1 in various types of cells, including human peripheral blood mononuclear cell (PBMC) T-cells, but exhibits aberrant nuclear entry in Jurkat cells. Ectopic expression of a JNK1 mutant defective of nuclear entry or a nuclear JNK inhibitor leads to impaired UV-induced apoptosis in both PBMC T- and Jurkat cells. The same treatment shows no effect on Fas-mediated apoptosis of PBMC T-cells but sensitizes Jurkat cells to Fas-mediated apoptosis. Taken together, our work suggests that aberrant subcellular organization of the JNK pathway might render certain tumor cells resistant to Fas-mediated apoptosis.

INTRODUCTION

The c-Jun N-terminal protein kinase (JNK; also known as SAPK) is a member of the mitogen-activated protein kinase (MAPK) superfamily, which also includes extracellular signal-regulated kinase (ERK) and the p38 family of kinases (Hibi et al., 1993). JNK has two ubiquitously expressed isoforms, JNK1 and JNK2, and a tissue-specific isoform JNK3, with different splicing forms (p54 and p46; Chang and Karin, 2001; Lin, 2003; Weston and Davis, 2007). JNK is activated by sequential protein phosphorylation through a MAPK module; that is, MAPK kinase kinase (MAP3K) → MAPK kinase (MAP2K or MKK) → MAPK, in response to a variety of extracellular stimuli (Karin, 1995; Lin, 2003). Two MAP2Ks, JNK-activating kinase 1 and 2 (JNKK1/MKK4 and JNKK2/MKK7), and several MAP3Ks are involved in JNK activation (Lin, 2003). Once activated, JNK, especially the JNK1 isoform, phosphorylates and regulates the activity of several transcription factors such as c-Jun and c-Myc as well as nontranscription factors such as members of the Bcl-2 family proteins (Lin, 2003; Yu et al., 2004). Overwhelming evidence shows that JNK has a central role in regulating many cellular activities, from cell cycle progression to apoptosis (Chang and Karin, 2001; Lin, 2003; Weston and Davis, 2007).

Because of the differential localization of the substrates, the correct spatial-temporal regulation of MAPK signaling is a crucial determinant of biological outcome. Much effort has been invested in understanding the regulation of nuclear translocation of ERK in
response to stimuli. It has been well established that activation of ERK by growth factors and other ligands induces their translocation to the nucleus (Lenormand et al., 1993; Raman et al., 2007). This relocation allows ERK access to nuclear transcription factors and other nuclear proteins that are then phosphorylated and/or stabilized to bring about relevant changes in gene expression (Lenormand et al., 1993; Raman et al., 2007). The distribution of ERK is tightly regulated by multiple means. In addition to the microtubule cytoskeleton, one key MAP2K of ERK, MEK1, is considered to be one of the most important regulators of ERK localization (Reszka et al., 1995; Fukuda et al., 1997). MEK1 binds to ERK and harbors a strong nuclear export sequence (NES). Thus, it retains unphosphorylated ERK in the cytosol by binding to it and may escalate nuclear export of the unphosphorylated kinases (Fukuda et al., 1997; Raman et al., 2007). Overexpression of ERK in cells frequently drives the protein into the nucleus, presumably by overwhelming cytosolic binding sites (Costa et al., 2006; Raman et al., 2007).

Despite that ERK, JNK, and p38 share a large number of common substrates, the same depth of knowledge about the mechanisms of p38 and JNK localization is lacking. It has been reported that p38 is nuclear in resting cells and is exported to the cytosol following stimulation by a number of agents. This pattern of localization mirrors that of the p38 substrate MAPK-activated protein kinase 2 (MK2). Phosphorylation of MK2 by p38 within the nucleus causes export of the p38-MK2 complex, presumably to allow these kinases to phosphorylate cytosolic targets (Ben-Levy et al., 1998). Thus there might be marked differences between the subcellular organization of ERK, JNK, and p38 MAPK pathways.

Little is known about the mechanisms of JNK localization yet. It seems that JNK exhibits stress-induced redistribution from the cytoplasm to the nucleus, which has been demonstrated as essential for stress-induced cell death (Cavigelli et al., 1995; Lu et al., 2006; Oleinik et al., 2007; Zhang et al., 2007). However, accumulation of basal JNK activity in the nucleus has been frequently seen in tumor cells (Guo et al., 2005; Hui et al., 2007). Our previous report also revealed aberrant nuclear entry of JNK in Jurkat leukemia T-cells even without JNK hyperactivation (Cui et al., 2009). Because inhibition of JNK activity, especially JNK1 activity, in Jurkat cells results in augmented Fas-mediated apoptosis (Cui et al., 2009), it is possible that aberrant subcellular localization of JNK, especially JNK1 isoform, contributes to the resistance to Fas-mediated apoptosis. Thus it is of importance to investigate the mechanisms of JNK localization. A better understanding of JNK subcellular organization might make it possible to specifically block the aberrant nuclear entry of JNK and hence help elucidate how the aberrant nuclear entry of JNK regulates apoptosis in tumor cells.

RESULTS

Ectopic expression of JNK1 drives the protein into the nucleus regardless of phosphorylation, whereas both endogenous and exogenous MKK7 show predominant cytoplasm localization in resting 293T cells

As stated above, it is of interest to elucidate the mechanisms of JNK (especially JNK1 isoform) localization. For this purpose, indirect immunofluorescence microscopy was performed with a JNK1-specific antibody (sc1648). Endogenous JNK1 showed predominant cytoplasm localization in serum-starved 293T cells (Figure 1A), consistent with previous reports (Cavigelli et al., 1995; Lu et al., 2006; Zhang et al., 2007). To simplify the visualization of JNK1 localization, a mammalian expression vector encoding p46JNK1, the major splicing form of JNK1, with C-terminal green fluorescent protein (GFP) fusion was prepared and transfected into 293T cells. Unexpectedly, it was found that GFP-p46JNK1 located mostly in the nucleus with the exclusion of nucleoli in resting 293T cells (Figure 1A). Because no degradation of GFP-p46JNK1 fusion protein was detected (Figure 1B), it is unlikely that the release of free GFP causes the discrepancy. Nuclear cytoplasmic fractionation and subsequent immunoblotting (IB) analysis with another JNK1 antibody (clone G151-333) also revealed that GFP-p46JNK1 was predominantly nuclear, whereas endogenous p46JNK1 was predominantly cytoplasmic in resting 293T cells (Figure 1C). Because GFP-p46JNK1 fusion protein was activated to an extent similar to endogenous JNK upon UV treatment in 293T cells (Figure 1D), the discrepancy in the subcellular localization of endogenous JNK1 and GFP-p46JNK1 was not caused by potential changes in the global structure of the fusion protein. Furthermore, both HA-p46JNK1 and M2-p46JNK1 exhibited significant nuclear entry (Figure 1E and Supplemental Figure S2). Ectopic expression of HA-p46JNK1 antiproliferation factor (APF), in which the key phosphorylation sites Thr183 and Tyr185 required for JNK activation have been substituted by Ala and Phe, respectively (Yu et al., 2004; Weston and Davis, 2007), also resulted in significant nuclear entry of the exogenous protein to an extent similar to wild-type (WT) HA-p46JNK1 (Figure 1E). Taken together, these data suggest that in resting cells, ectopic expression of JNK1 drives the protein into the nucleus independent of phosphorylation, in contrast to the predominant cytoplasm localization of endogenous JNK1.

Upstream MAP2K of ERK, MEK1, is considered to be one of the most important regulators of ERK localization (Reszka et al., 1995; Fukuda et al., 1997). It remains unknown whether MAP2Ks of JNK play a role in the subcellular organization of JNK. Because MKK4 activates both JNK and p38, whereas MKK7 activates only JNK activity (Zeng et al., 1999; Lin, 2003), we set out to investigate the subcellular organization of MKK7. For this purpose, indirect immunofluorescence microscopy was performed with an MKK7-specific antibody (sc7104). Endogenous MKK7 showed exclusive cytoplasm localization in resting 293T cells (Figure 1F). It is interesting that GFP-MKK7 also exhibited significant cytoplasm localization in resting cells (Figure 1F). Nuclear cytoplasmic fractionation and subsequent IB analysis with another MKK7 antibody (no. 4172) revealed that GFP-MKK7 was predominantly cytoplasmic, even though a small portion was nuclear, whereas endogenous MKK7 was exclusively cytoplasmic in serum-starved 293T cells (Figure 1G). Furthermore, indirect immunofluorescence microscopy showed that both HA-MKK7 WT and its kinase-dead mutant HA-MKK7 KM (Tournier et al., 2001) were mostly cytoplasmic (Figure 1H). Thus, our data suggest that both endogenous and exogenous MKK7 show predominant cytoplasm localization independent of their kinase activity in resting cells.

MKK7 anchors JNK1 in the cytoplasm via its N-terminal JNK-binding domain (JBD) in resting 293T and NIH3T3 cells

The subcellular localization of endogenous and exogenous JNK1 and MKK7 in resting 293T cells mimics that of endogenous and exogenous ERK and MEK1, respectively (Lenormand et al., 1993; Fukuda et al., 1997; Costa et al., 2006; Raman et al., 2007). It has been well established that MEK1 retains unphosphorylated ERK in the cytosol by binding to it (Fukuda et al., 1997; Raman et al., 2007). It is possible that MKK7 might work as a cytoplasmic anchoring protein for JNK1 in resting cells, just like MEK1 does in the case of ERK. To test this scenario, 293T cells were transfected with a mammalian expression vector encoding HA-p46JNK1, with cotransfection of the plasmid harboring GFP-MKK7 WT, GFP-MKK7 KM, or GFP. HA-p46JNK1 still showed nuclear accumulation with the coexpression of GFP in serum-starved 293T cells (Figure 2A). However, GFP-MKK7...
MKK7 is composed of an N-terminal JNK-binding domain (amino acids 1–119) and a kinase domain (amino acids 120–419) (McDonald et al., 2000; Amagasaki et al., 2006; Bardwell et al., 2009). To investigate which domain is responsible for the anchoring, we constructed a C-terminal truncated HA-MKK7 1–119 and an N-terminal truncated HA-MKK7 120–419 (Figure 2D).

Indirect immunofluorescence microscopy revealed that HA-MKK7 1–119 was mostly cytoplasmic, whereas HA-MKK7 120–419 distributed evenly throughout the cell (Figure 2D), suggesting that the cytoplasm localization of MKK7 depends on its N-terminal part. Consistently, HA-MKK7 1–119, but not HA-MKK7 120–419, significantly reversed the nuclear accumulation of GFP-p46JNK1 in resting 293T cells (Figure 2E). Taken together, these data suggest that MKK7 anchors JNK1 via its N-terminal JNK-binding domain.

MKK7 works as a cytoplasmic anchoring protein for various JNK isoforms and splicing forms in resting 293T cells.

JNK has two ubiquitously expressed isoforms, JNK1 and JNK2, with different splicing forms (p54 and p46; Chang and Karin, 2001; Lin, 2002). WT or GFP-MKK7 KM coexpression significantly reversed the nuclear accumulation of HA-p46JNK1 under the same conditions (Figure 2A). Similar phenomena were also seen in resting NIH3T3 cells (Figure 2A).

By contrast, GFP-NES-JBD showed no effect on the nuclear accumulation of HA-p46JNK1, even though this fusion protein distributed predominantly in the cytoplasm of serum-starved 293T cells (Figure 2A) and has been shown to interact with JNK (Bjorkblom et al., 2005; Tararuk et al., 2006). To further test the role of MKK7 in the subcellular localization of JNK1, 293T cells were transfected with a mammalian expression vector encoding GFP-p46JNK1, with cotransfection of the plasmid harboring HA-MKK7 WT, HA-MKK7 KM, or HA-MKK6. GFP-p46JNK1 still showed nuclear accumulation with the coexpression of HA-MKK6 in resting 293T cells (Figure 2B). However, HA-MKK7 WT or HA-MKK7 KM coexpression significantly reversed the nuclear accumulation of GFP-p46JNK1 under the same conditions (Figure 2B), even though it did not make the nucleus empty of the exogenous GFP-p46JNK1 protein. Furthermore, knockdown of endogenous MKK7 resulted in the nuclear entry of endogenous JNK1 (Figure 2C). Taken together, our data suggest a role for MKK7 to anchor JNK1 in the cytoplasm in resting cells.
proteins under the same conditions (Figure 3C). Thus MKK7 works as a cytoplasmic anchoring protein for various JNK isoforms and splicing forms, not just for p46JNK1.

Cytoplasmic localization of JNK1 is not essential for its activation

The activation of JNK depends on its upstream kinases, namely, MKK7 and MKK4. Clearly MAP2Ks and JNK must interact and therefore have to be in the same cellular compartment. Thus it is possible that anchoring of JNK1 in the cytoplasm by MKK7 in resting cells might facilitate the activation of JNK1. To test this hypothesis, the chimera p46JNK1 protein bearing the nuclear localization signal (NLS) was constructed; a nine-amino acid stretch containing the NLS from the C-terminus of a processivity factor of Kaposi's

FIGURE 2: MKK7 anchors JNK1 in the cytoplasm via its N-terminal JNK-binding domain in resting 293T and NIH3T3 cells. (A) 293T and NIH 3T3 cells were transfected with a mammalian expression vector encoding HA-p46JNK1, with cotransfection of the plasmid harboring GFP-MKK7 WT, GFP-MKK7 KM, GFP-NES-JBD, or GFP. Then 24 h after transfection, the cells were serum starved, fixed, and stained with an HA antibody. (B) 293T cells were transfected with a mammalian expression vector encoding GFP-p46JNK1, with cotransfection of the plasmid harboring HA-MKK6, HA-MKK7 WT, or HA-MKK7 KM. Then the cells were treated as described in (A). (C) 293T cells were transfected with MKK7 siRNA or the control scramble siRNA and cultured for 48 h. Cell lysates were prepared and expression of MKK7 and actin was determined by IB (Top). Ctrl, Control. The subcellular localization of endogenous JNK1 was measured as described in Figure 1A (Bottom). (D) Schematic presentation (Top) and subcellular localization (Bottom) of truncated MKK7 constructs. (E) 293T cells were transfected with a mammalian expression vector encoding GFP-p46JNK1, with cotransfection of the plasmid harboring HA-MKK7 1–119 or HA-MKK7 120–419. Then the cells were treated as described in (A). The arrows in (A) and (B) indicate that the cells without exogenous MKK7 show nuclear accumulation of exogenous JNK1, whereas the other cell in the same field with exogenous MKK7 shows cytoplasmic localization of exogenous JNK1.

2003; Weston and Davis, 2007). Thus it is of interest whether p46JNK1, p54JNK1, p46JNK2, and p54JNK2 are similarly regulated by MKK7. For this purpose, HA-p46JNK1, HA-p54JNK1, HA-p46JNK2, and HA-p54JNK2 were all cloned into pcDNA3.1 (+) vector and transfected into 293T cells. IB analysis with a JNK1 antibody (clone G151-333) or a JNK2 antibody (no. 9252) confirmed the ectopic expression of these different JNK isoforms and splicing forms (Figure 3A). Consistent with the previous data, indirect immunofluorescence microscopy revealed that all these exogenous JNK proteins showed significant nuclear entry (Figure 3B). HA-p46JNK1, HA-p54JNK1, HA-p46JNK2, and HA-p54JNK2 still showed nuclear accumulation with the coexpression of GFP in resting 293T cells (Figure 3C). However, coexpression with GFP-MKK7 KM significantly reversed the nuclear accumulation of all these exogenous JNK proteins under the same conditions (Figure 3C). Thus MKK7 works as a cytoplasmic anchoring protein for various JNK isoforms and splicing forms, not just for p46JNK1.
MKK7 works as a cytoplasmic anchoring protein for various JNK isoforms and splicing forms in resting 293T cells. (A) The expression of HA-p46JNK1, HA-p54JNK1, HA-p46JNK2, and HA-p54JNK2 in resting 293T cells was determined by IB with a JNK1 antibody (clone G151-333) or a JNK2 antibody (no. 9252). (B) The subcellular localization of HA-p46JNK1, HA-p54JNK1, HA-p46JNK2, and HA-p54JNK2 in resting 293T cells was examined by indirect immunofluorescence staining with an HA antibody. (C) 293T cells were transfected with mammalian expression vectors encoding HA-p46JNK1, HA-p54JNK1, HA-p46JNK2, and HA-p54JNK2, respectively, with cotransfection of the plasmid harboring GFP-MKK7 KM or GFP. Then 24 h after transfection, the cells were serum starved, fixed, and stained with an HA antibody.

FIGURE 3: MKK7 works as a cytoplasmic anchoring protein for various JNK isoforms and splicing forms in 293T cells. (A) The expression of HA-p46JNK1, HA-p54JNK1, HA-p46JNK2, and HA-p54JNK2 in resting 293T cells was determined by IB with a JNK1 antibody (clone G151-333) or a JNK2 antibody (no. 9252). (B) The subcellular localization of HA-p46JNK1, HA-p54JNK1, HA-p46JNK2, and HA-p54JNK2 in resting 293T cells was examined by indirect immunofluorescence staining with an HA antibody. (C) 293T cells were transfected with mammalian expression vectors encoding HA-p46JNK1, HA-p54JNK1, HA-p46JNK2, and HA-p54JNK2, respectively, with cotransfection of the plasmid harboring GFP-MKK7 KM or GFP. Then 24 h after transfection, the cells were serum starved, fixed, and stained with an HA antibody.

MKK7 also works as a cytoplasmic anchoring protein for JNK1 in human peripheral blood mononuclear cell (PBMC) T-cells, but not in Jurkat human leukemic T-cells

Our previous report revealed aberrant nuclear entry of JNK protein, including JNK1 protein, in Jurkat human leukemic T-cells even without JNK hyperactivation (Cui et al., 2009). Clearly MKK7 fails to anchor JNK1 in the cytoplasm in Jurkat cells. Because cytoplasmic localization of JNK1 is not essential for its activation, the anchoring of JNK by MKK7 in the cytoplasm of nonmalignant cells might hinder JNK from contributing to tumorigenesis. Therefore it is of importance to explore why MKK7 fails to anchor JNK1 in Jurkat cells. IB analysis revealed that the protein levels of MKK7 and JNK1 in Jurkat cells were similar to those in human PBMC T-cells (Figure 5A). Thus the aberrant subcellular localization of JNK1 is not due to abundance of JNK1 protein or deficiency of MKK7 protein. Nuclear cytoplasmic fractionation and subsequent IB analysis revealed that endogenous phospho-JNK, JNK, and MKK7 exhibited cytoplasmic localization in human PBMC T-cells (Figure 5B). However, aberrant nuclear accumulation of basal JNK activity in Jurkat human leukemic T-cells was associated with aberrant nuclear entry of endogenous JNK and MKK7 (Figure 5B). The aberrant nuclear entry of endogenous MKK7 in Jurkat cells was confirmed by indirect immunofluorescence microscopy (Figure 5C). Furthermore, nuclear cytoplasmic fractionation and subsequent IB analysis revealed that knockdown of endogenous MKK7 in human PBMC T-cells resulted in the nuclear entry of JNK2 (both p46JNK2 and p54JNK2) as well as JNK1 (Figure 5D), consistent with the notion that MKK7 works as a cytoplasmic anchoring protein for various JNK isoforms and splicing forms. The nuclear entry of JNK1 in normal T-cells under the condition of MKK7 deficiency was confirmed by indirect immunofluorescence microscopy (Figure 5D). Thus MKK7 also anchors JNK1 in the cytoplasm in normal T-cells. Taken together, these data suggest that the failure of MKK7 to anchor JNK1 in Jurkat human leukemic T-cells results from, at least partially, the aberrant nuclear entry of MKK7.

It is of great interest why endogenous MKK7 showed aberrant nuclear entry in Jurkat cells. PCR amplification of the open reading frame of MKK7 and subsequent sequencing excluded the possibility of N-terminal deletion or mutation of MKK7 in Jurkat cells (unpublished data). To further investigate the underlying mechanism, GFP-MKK7 was transfected into human PBMC T-cells and Jurkat cells. If the aberrant nuclear entry of MKK7 in Jurkat cells results from the deficiency of some anchoring cytoplasmic protein(s), which is unlikely because exogenous MKK7 exhibited predominant cytoplasmic localization in 293T and NIH3T3 cells, overexpressed GFP-MKK7 should show more significant nuclear accumulation in Jurkat cells. However, if aberrant MKK7 nuclear entry in Jurkat cells results from the abundance of some nuclear MKK7-binding protein(s), overexpressed GFP-MKK7 should show predominant cytoplasmic localization in Jurkat cells. Indeed, a low level of GFP-MKK7 expression (dim) in Jurkat cells led to diffused subcellular localization, similar to endogenous MKK7 (Figure 5E). However, a high level of GFP-MKK7 expression (bright) in Jurkat cells resulted in predominant cytoplasmic localization, though with significant nuclear entry (Figure 5E). By contrast, GFP-MKK7 was exclusively cytoplasmic in human PBMC T-cells (Figure 5E). Taken together, these data suggest that some MKK7-binding nuclear protein(s), which might show overexpression in certain malignant cells including Jurkat cells, mediate the aberrant nuclear entry of endogenous MKK7.
Nuclear entry of exogenous JNK1 depends on its C-terminal sequence

Because MKK7 loses its cytoplasmic localization in Jurkat cells, aberrant nuclear entry of JNK1 in these cells could not be blocked by mimicking the anchoring role of MKK7. Another possible way to block the aberrant nuclear entry of JNK1 is to transfected the cells with a JNK1 mutant defective for nuclear entry. To investigate the structural basis for the nuclear entry of exogenous JNK1, we constructed various GFP-p46JNK1 truncated mutants. Transient transfection into 293T cells revealed that GFP-p46JNK1Δ1–83 and GFP-p46JNK1Δ250–384 exhibited similar distribution to GFP-p46JNK1 WT, whereas GFP-p46JNK1Δ250–384 was exclusively cytoplasmic (Figure 6A), suggesting that the nuclear entry depends on the C-terminal part of the protein. Further exploration showed that both GFP-p46JNK1Δ302–384 and GFP-p46JNK1Δ342–384 were exclusively cytoplasmic, whereas GFP-p46JNK1Δ250–341 distributed diffusely in the cytoplasm and the nucleus (Figure 6A). These data suggest that amino acids 250–341 are dispensable for the nuclear entry of JNK1, but the sequence in the far C-terminal part is essential. Consistent with these observations, both GFP-p46JNK1D326A/S328A and GFP-p46JNK1D326E/S328E evenly distributed throughout the cell (Figure 6B), despite the fact that the DPS (Asp326-Pro327-Ser328) motif in JNK1 has been suggested as the nuclear translocation signal (NTS) (Chuderland et al., 2008). These data suggest that the mechanism underlying JNK1 nuclear translocation is different from ERK (Chuderland et al., 2008). Moreover, GFP-p46JNK1Δ356–384 was exclusively cytoplasmic, whereas GFP-p46JNK1Δ370–384 was both cytoplasmic and nuclear (Figure 6B). Because GFP-p46JNK1Δ356–384 was activated to an extent similar to GFP-p46JNK1 WT with HA-MKK7 WT coexpression in 293T cells (Supplemental Figure S3), the absence of GFP-p46JNK1Δ356–384 in the nucleus was not caused by potential changes in the global structure of the fusion protein. Taken together, these data suggest that nuclear translocation of JNK1 is mediated by amino acids 342–369 of the protein.

Ectopic expression of a JNK1 mutant defective for nuclear entry or a nuclear JNK inhibitor shows no effect on Fas-mediated apoptosis of human PBMC T-cells but sensitizes Jurkat cells to Fas-mediated apoptosis

GFP-p46JNK1 WT exhibited more significant nuclear localization in response to UV, whereas GFP-p46JNK1Δ356–384 remained in the cytoplasm under the same conditions (Figure 7A). Because the nuclear JNK1 activity has been demonstrated as essential for UV-induced apoptosis (Lu et al., 2006), if GFP-p46JNK1Δ356–384 antagonizes UV-induced apoptosis, this mutant protein should block the nuclear entry of endogenous JNK1. To test this hypothesis, both human PBMC T-cells and Jurkat human leukemic T-cells were transfected with expression vectors encoding GFP, GFP-p46JNK1Δ356–384, and GFP-NLS-JBD, which has been demonstrated to act as a nuclear JNK inhibitor (Bjorkblom et al., 2005; Tararuk et al., 2006), respectively, followed by stimulation with or without UV. Apoptosis assay revealed that ectopic expression of GFP-p46JNK1Δ356–384 led to impaired UV-induced apoptosis, similar to GFP-NLS-JBD (Figure 7B). Thus, GFP-p46JNK1Δ356–384 could block the nuclear entry of endogenous JNK1. Next, we tried to investigate how blockade of nuclear JNK activity with GFP-p46JNK1Δ356–384 and GFP-NLS-JBD would affect Fas-mediated apoptosis in normal T-cells and Jurkat cells. Apoptosis assay revealed that ectopic expression of both proteins showed no effect on Fas-mediated apoptosis of human PBMC T-cells but resulted in augmented apoptosis in Jurkat human leukemic T-cells upon Fas ligation (Figure 7C). Thus aberrant subcellular organization of the JNK pathway might render certain tumor cells resistant to Fas-mediated apoptosis.

The mechanism by which blockade of nuclear JNK activity sensitized Jurkat cells, but not normal T-cells, to Fas-mediated cell death was further explored. IB analysis revealed that UV irradiation significantly activated JNK in human PBMC cells, whereas anti-human Fas antibody treatment showed marginal effect on JNK phosphorylation (Figure 7D). Accordingly, UV irradiation led to significant JNK nuclear localization 30 min after the treatment (Figure 7E), as reported previously (Cavigelli et al., 1995; Lu et al., 2006), whereas anti-human Fas antibody treatment exhibited no effect on JNK subcellular localization (Figure 7E). Our data are consistent with previous reports that Fas ligation only weakly activates JNK and does not lead to JNK-dependent phosphorylation of nuclear transcription factors (Low et al., 1999; Schwabe et al., 2004). Surprisingly, UV radiation also induced weak nuclear entry of MKK7 60 min after the treatment, whereas anti-human Fas antibody treatment had no such effect (Figure 7E). Because there was little basal nuclear JNK activity found in human PBMC T-cells (Figure 5B) (Cui et al., 2009), it is reasonable that blockade of nuclear JNK activity showed no effect on Fas-mediated apoptosis in these normal T-cells. By contrast, Jurkat cells exhibited aberrant nuclear accumulation of basal JNK activity (Figure 5B) (Cui et al., 2009). Because basal JNK activity, especially JNK1 activity, in Jurkat cells maintains the protein level of Bcl-2 (Cui et al., 2009), and the protein level of Bcl-2
that MKK7 might work as a cytoplasmic anchoring protein for JNK1 in nonmalignant cells since the nuclear accumulation of exogenous JNK1 is significantly reversed by coexpression of MKK7 and knockdown of endogenous MKK7 resulted in the nuclear entry of endogenous JNK1. The regulation of JNK localization also resembles ERK in another way: Robust JNK activation induced by UV exposure leads to JNK nuclear entry (30 min after UV treatment) earlier than MKK7 nuclear entry (60 min after UV treatment). Thus, phosphorylation of JNK might lead to conformational changes of the protein and consequent release from MKK7 within 30 min after UV treatment, similar to the release of ERK from MEK1 upon ERK phosphorylation (Fukuda et al., 1997; Raman et al., 2007). However, activation of the ERK pathway does not lead to nuclear entry of MKK7 (Fukuda et al., 1997; Raman et al., 2007); it is unclear why late and weak nuclear localization of MKK7 happens in the case of UV-induced JNK activation. There is no NES identified in JNK. However, our data and previous studies have revealed that exogenous JNK1 or other JNK isoforms showed significant nuclear entry (McDonald et al., 2000; Bruna et al., 2003; Amagasaki et al., 2006). It remains unclear how JNK gets into the nucleus. Our data suggest that the nuclear entry of JNK1 does not depend on its phosphorylation, similar to the nuclear entry of ERK (Lenormand et al., 1993; Raman et al., 2007). Recent progress suggests that a three–amino acid domain (SPS) determines the sensitivity to Fas-mediated apoptosis (Mignon et al., 1998; Zhou et al., 1998), it is possible that blockade of nuclear JNK activity might result in a reduced level of Bcl-2. Indeed, IB analysis revealed that ectopic expression of GFP-p46JNK1Δ356–384 and GFP-NLS-JBD led to a reduced level of Bcl-2 (Figure 7E). Thus aberrant subcellular organization of the JNK pathway might render certain tumor cells resistant to Fas-mediated apoptosis by maintaining the protein level of Bcl-2.

**DISCUSSION**

Because of the differential localization of the substrates, the correct spatial-temporal regulation of MAPK signaling is a crucial determinant of biological outcome. Previous studies suggest there might be marked differences between the subcellular organization of ERK and p38 pathways. However, little is known about the mechanisms of JNK localization. In this work, we show that, at least in certain cell contexts, the regulation of JNK localization might be similar to ERK. The endogenous JNK1 exhibited predominant cytoplasm localization in nonmalignant cells, whereas the ectopic expression of JNK1 drove the protein into the nucleus. On the other hand, both endogenous and exogenous MKK7, the upstream kinase of JNK, showed predominant cytoplasmic localization in nonmalignant cells despite the fact that there is no NES identified in MKK7. Further exploration revealed that MKK7 might work as a cytoplasmic anchoring protein for JNK1 in nonmalignant cells since the nuclear accumulation of exogenous JNK1 is significantly reversed by coexpression of MKK7 and knockdown of endogenous MKK7 resulted in the nuclear entry of endogenous JNK1. The regulation of JNK localization also resembles ERK in another way: Robust JNK activation induced by UV exposure leads to JNK nuclear entry (30 min after UV treatment) earlier than MKK7 nuclear entry (60 min after UV treatment). Thus, phosphorylation of JNK might lead to conformational changes of the protein and consequent release from MKK7 within 30 min after UV treatment, similar to the release of ERK from MEK1 upon ERK phosphorylation (Fukuda et al., 1997; Raman et al., 2007). However, activation of the ERK pathway does not lead to nuclear entry of MKK7 (Fukuda et al., 1997; Raman et al., 2007); it is unclear why late and weak nuclear localization of MKK7 happens in the case of UV-induced JNK activation.

There is no NLS identified in JNK. However, our data and previous studies have revealed that exogenous JNK1 or other JNK isoforms showed significant nuclear entry (McDonald et al., 2000; Bruna et al., 2003; Amagasaki et al., 2006). It remains unclear how JNK gets into the nucleus. Our data suggest that the nuclear entry of JNK1 does not depend on its phosphorylation, similar to the nuclear entry of ERK (Lenormand et al., 1993; Raman et al., 2007). Recent progress suggests that a three–amino acid domain (SPS) in
ERK also appears in many cytonuclear shuttling proteins and might act as a general NTS (Chuderland et al., 2008). The phosphorylation of the Ser residues in this region was shown to be important for the mechanism of translocation (Chuderland et al., 2008). In the case of JNK1, a similar sequence (D326P327S328) has been suggested to facilitate the nuclear entry of the protein because one of the amino acids next to Pro is acidic before any phosphorylation (Chuderland et al., 2008). However, our data suggest that this motif is not essential for the nuclear entry of JNK1 because GFP-p46JNK1Δ250–341, GFP-p46JNK1D326A/S328A, and GFP-p46JNK1D326E/S328E were evenly distributed throughout the cell. Moreover, GFP-p46JNK1Δ302–384, GFP-p46JNK1Δ342–384, and GFP-p46JNK1Δ356–384 were exclusively cytoplasmic, whereas GFP-p46JNK1Δ370–384 was both cytoplasmic and nuclear, which suggests that nuclear translocation of JNK1 is mediated by amino acids 342–369 of the protein. How this subdomain mediates the nuclear entry of JNK1 remains to be explored.

No NES sequence has been identified in MKK7. Previous data about the specific subcellular localization of MKK7 are controversial (Tournier et al., 1999; Ho et al., 2006). Here we show that MKK7 works as a cytoplasmic anchoring protein for JNK1 in nonmalignant 293T, NIH3T3, and human PBMC T-cells. However, clearly such regulation is lost in certain tumor cells, including Jurkat human leukemic T-cells. Because cytoplasmic localization of JNK1 is not essential for its activation, defective anchoring of JNK1 in the cytoplasm by MKK7 might contribute to tumorigenesis. Indeed, blockade of nuclear JNK activity leads to a reduced level of Bcl-2, which is associated with augmented apoptosis in Jurkat cells upon Fas ligation. It remains unknown why MKK7 loses NES-independent cytoplasm localization in certain malignant cells, including Jurkat cells. Our data suggest that some MKK7-binding nuclear protein(s), which might show overexpression in such malignant cells, mediate the aberrant nuclear entry of endogenous MKK7. There is no known MKK7-binding nuclear protein yet. However, recent progress has demonstrated that the Drosophila ATAC (Ada-two-A-containing) histone acetyltransferase complex recruits proteins related to the JNK pathway such as MKK4 and JNK, which is essential for Drosophila ATAC to serve as a transcriptional cofactor for c-Jun at certain JNK target genes. Relocalization of proteins related to the JNK pathway by Drosophila ATAC is dependent on the CG10238 subunit of ATAC (Suganuma et al., 2010). MAPK upstream kinase-binding inhibitory protein (MBIP), the corresponding component of CG10238 in the human ATAC complex, has been revealed to exhibit overexpression in certain tumor cells (Yasui et al., 2001; Weir et al., 2007). Consistently, our preliminary data suggest that MBIP might be involved in the cytoplasmic localization of MKK7.
MKK7 (no. 4172) were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against hemagglutinin (HA), Xpress-tag, JNK1 (sc1648), MKK7 (sc7104), IκBα, c-Jun, Bcl-2, and actin were from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant human interleukin (IL)-2 and antibodies against JNK1 (clone G151-333), human CD3, and human Fas (clone CH11) were purchased from BD Biosciences (Franklin Lakes, NJ). Antibody against GFP was from eBioscience (San Diego, CA). The enhanced chemiluminescence kit was obtained from Amersham (Arlington Heights, IL). Antibody overexpressed in Jurkat human leukemic T-cells (Supplemental Figure S4). It is possible that CG10238 also promotes the nuclear localization of MKK7 and MBIP has a similar role. Future studies are required to address these issues.

**MATERIALS AND METHODS**

**Reagents**
Fetal bovine serum (FBS) was purchased from HyClone Laboratories (Logan, UT). Antibodies against phospho-JNK, JNK2 (no. 9252), and MKK7 (no. 4172) were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against hemagglutinin (HA), Xpress-tag, JNK1 (sc1648), MKK7 (sc7104), IκBα, c-Jun, Bcl-2, and actin were from Santa Cruz Biotechnology (Santa Cruz, CA). Recombinant human interleukin (IL)-2 and antibodies against JNK1 (clone G151-333), human CD3, and human Fas (clone CH11) were purchased from BD Biosciences (Franklin Lakes, NJ). Antibody against GFP was from eBioscience (San Diego, CA). The enhanced chemiluminescence kit was obtained from Amersham (Arlington Heights, IL).
against FLAG-tag (M2) and 4',6-diamidine-2-phenylindole (DAPI) were from Sigma Chemical (St. Louis, MO). Fluorescein isothiocyanate– or phycoerythrin (PE)-conjugated secondary antibodies were from Jackson ImmunoResearch Laboratories (West Grove, PA). Small interfering RNA (siRNA) that targets human MKK7 (NM_145185) was designed based on nucleotides 464 to 482 relative to the translation start site and purchased from Dharmacon (Lafayette, CO). Lipo- fectamine 2000 was from Invitrogen (Carlsbad, CA).

**Plasmids**

pSrXα-HA-p46JNK1 and pSrXα-HA-MKK7-p46JNK1 have been described previously (Zheng et al., 1999; Zhang et al., 2005). APF mutation was introduced into pSrXα-HA-p46JNK1 using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA), and the mutation was verified by DNA sequencing. Constructs for GFP-p46JNK1 WT and its mutants GFP-p46JNK1Δ1–83, GFP-p46JNK1Δ250–384, GFP-p46JNK1Δ250–341, GFP-p46JNK1Δ326A/S328A, GFP-p46JNK1Δ232E/S328E, GFP-p46JNK1Δ356–384, and GFP-p46JNK1Δ370–384 were generated by PCR, subcloned into pEGFP-N1 vector, and confirmed by DNA sequencing. pcDNA3.1-HA-p46JNK1, pcDNA3.1-HA-p54JNK1, pcDNA3.1-HA-p46JNK2, pcDNA3.1-HA-p54JNK2, pcDNA3.1-Xpress-NLS-p46JNK1, pcDNA3.1-HA-MKK7 WT, pcDNA3.1-HA-MKK7 KM, pcDNA3.1-HA-MKK7 1–119, pcDNA3.1-HA-MKK7 120–419, GFP-MKK7 WT, and GFP-MKK7 KM were generated by cloning PCR-amplified products into pcDNA3.1 (+) vector and pEGFP-N1 vector, respectively, and confirmed by DNA sequencing. GFP-NES-JBD and GFP-NLS-JBD were described previously (Bjorkblom et al., 2005; Tararak et al., 2006).

**Cell culture and transfection**

293T, NIH3T3, and Jurkat cells were grown in DMEM or RPMI 1640 supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, and 100 µg/ml streptomycin. Transfection of 293T, NIH3T3, and Jurkat cells was performed by using Lipofectamine 2000 according to the manufacturer's protocol. Human PBMCs were isolated from the heparinized peripheral blood of healthy volunteers by density gradient centrifugations. Freshly isolated blood T lymphocytes are resistant to Fas-mediated apoptosis. They become sensitive to this form of apoptosis only after in vitro activation with anti-TCR/CD3 or with anti-CD3 for 24 h and then cultured in complete medium supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin. Transfection of 293T, NIH3T3, and Jurkat cells was performed by using Lipofectamine 2000 according to the manufacturer's protocol.

**Immunofluorescence and nuclear cytoplasmic fractionation**

Immunofluorescence and nuclear cytoplasmic fractionation were performed as previously described (Cui et al., 2009).

**Apoptosis assays**

Dual staining with PE-conjugated Annexin V and 7AAD was carried out to detect the induction of apoptotic cell death. Cells were washed with phosphate-buffered saline and resuspended in 200 µl HEPES buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.8 mM CaCl2) containing 10 µl Annexin V-FITC and 10 µl 7AAD (ApoScreenTM Annexin V-FITC kit; SouthernBiotech, Birmingham, AL). Following incubation for 15 min at room temperature, cells were analyzed by flow cytometry (FACSCalibur; BD Biosciences). The percentages of Annexin V–positive cells in 7AAD-negative/GFP-positive populations were analyzed.

**Statistical analysis**

The data were shown as mean ± standard deviations. The Student's t-test was used to compare the difference between the two groups. The difference was considered statistically significant when p < 0.05.

**ACKNOWLEDGMENTS**

We are grateful to Anning Lin, Eleanor T. Coffey, Xuemin Zhang, and Lingjiang Zhang for helpful discussion and/or reagents that made this work possible. This work was supported by grants from the National Natural Science Foundation of China (30973547), Key Natural Science Program of Beijing (71010008), National Key Technologies R & D Program for New Drugs (2009ZX09301-002), and National Key Basic Research Program of China (2010CB911904).

**REFERENCES**

Amagasaki K, Kaneto H, Heldin CH, Lennarsson J (2006). c-Jun N-terminal kinase is necessary for platelet-derived growth factor-mediated chemotaxis in primary fibroblasts. J Biol Chem 281, 21713–21719.

Bardwell AJ, Frankson E, Bardwell L (2009). Selectivity of docking sites in MAPK kinases. J Biol Chem 284, 13165–13173.

Ben-Levy R, Hooper S, Wilson R, Paterson HF, Marshall CJ (1998). Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Curr Biol 8, 1049–1057.

Bjorkblom B, Ostman N, Hongisto V, Komarovsky V, Filen JJ, Nyman TA, Kallunki T, Courtney MJ, Coffey ET (2005). Constitutively active cytoplasmic c-Jun N-terminal kinase 1 is a dominant regulator of dendritic architecture role of microtubule-associated protein 2 as an effector. J Neurosci 25, 6350–6361.

Bruna A, Nicolas M, Munoz A, Kyrakis JM, Caells C (2003). Glucocorticoid receptor-JNK interaction mediates inhibition of the JNK pathway by glucocorticoids. EMBO J 22, 6035–6044.

Cavigelli M, Dolfi F, Clarex FT, Karin M (1995). Induction of c-fos expression through JNK-mediated TCF/Etk-1 phosphorylation. EMBO J 14, 5957–5964.

Chang L, Karin M (2001). Mammalian MAP kinase signalling cascades. Nature 410, 37–40.

Chen Y, Ciustea M, Ricciardi RP (2005). Dynamic regulation of ERK2 nuclear translocation and mobility in living cells. J Cell Sci 119, 4952–4963.

Cui J, Wang Q, Wang J, Lu M, Zhu N, Li Y, Feng J, Shen B, Zhang J (2009). Basal c-Jun NH2-terminal protein kinase activity is essential for survival and proliferation of T-cell acute lymphoblastic leukemia cells. Mol Cancer Ther 8, 3214–3222.

Fukuda M, Gotoh Y, Nishida E (1997). Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBO J 16, 1901–1908.

Gendron S, Couture J, Aoudjit F (2003). Integrin α2β1 inhibits Fas-mediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway. J Biol Chem 278, 48633–48643.

Guo L, Guo Y, Xiao S, Shi X (2005). Protein kinase p-JNK is correlated with the activation of AP-1 and its associated Jun family proteins in hepatocellular carcinoma. Life Sci 77, 1869–1878.

Hibi M, Lin A, Smeal T, Minden A, Karin M (1993). Identification of an oncprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes Dev 7, 2135–2148.
Suganuma T, Mushegian A, Swanson SK, Abmayr SM, Florens L, Washburn MP, Workman JL (2010). The ATAC acetyltransferase complex coordinates MAP kinases. Cell 142, 726–736.

Tararuk T et al. (2006). JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length. J Cell Biol 173, 265–277.

Tournier C, Dong C, Turner TK, Jones SN, Flavell RA, Davis RJ (2001). MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. Genes Dev 15, 1419–1426.

Tournier C, Whitmarsh AJ, Cavanagh J, Barrett T, Davis RJ (1999). The MKK7 gene encodes a group of c-Jun NH2-terminal kinase kinases. Mol Cell Biol 19, 1569–1581.

Weir BA et al. (2007). Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893–898.

Weston CR, Davis RJ (2007). The JNK signal transduction pathway. Curr Opin Cell Biol 19, 142–149.

Yasui K, Imoto I, Fukuda Y, Pimkhaokham A, Yin ZQ, Naruto T, Shimada Y, Nakamura Y, Inazawa J (2001). Identification of target genes within an amplicon at 14q12-q13 in esophageal squamous cell carcinoma. Genes Chromosomes Cancer 32, 112–118.

Yu C, Minemoto Y, Zhang J, Liu J, Tang F, Bui TN, Xiang J, Lin A (2004). JNK suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD. Mol Cell 13, 329–340.

Zhang J, Liu J, Yu C, Lin A (2005). BAD Ser128 is not phosphorylated by c-Jun NH2-terminal kinase for promoting apoptosis. Cancer Res 65, 8372–8378.

Zheng C, Xiang J, Hunter T, Lin A (1999). The JNKK2-JNK1 fusion protein acts as a constitutively active c-Jun kinase that stimulates c-Jun transcription activity. J Biol Chem 274, 28966–28971.

Zhou M, Gu L, Yeager AM, Findley HW (1998). Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression. Leukemia 12, 1756–1763.

Zhu N, Cui J, Qiao C, Li Y, Ma Y, Zhang J, Shen B (2008). cAMP modulates macrophage development by suppressing M-CSF-induced MAPKs activation. Cell Mol Immunol 5, 153–157.